Cargando…

Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer’s disease

PURPOSE: In order to maximise the utility of [(11)C]-PBR28 for use in longitudinal studies and clinical trials in Alzheimer’s disease (AD), there is a need to develop non-invasive metrics of tracer binding that do not require arterial cannulation. Recent work has suggested that standardised uptake v...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Akshay, Veronese, Mattia, Xu, Xiaohui, Curtis, Charles, Turkheimer, Federico, Howard, Robert, Reeves, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039146/
https://www.ncbi.nlm.nih.gov/pubmed/27678494
http://dx.doi.org/10.1186/s13550-016-0226-3
_version_ 1782455999210192896
author Nair, Akshay
Veronese, Mattia
Xu, Xiaohui
Curtis, Charles
Turkheimer, Federico
Howard, Robert
Reeves, Suzanne
author_facet Nair, Akshay
Veronese, Mattia
Xu, Xiaohui
Curtis, Charles
Turkheimer, Federico
Howard, Robert
Reeves, Suzanne
author_sort Nair, Akshay
collection PubMed
description PURPOSE: In order to maximise the utility of [(11)C]-PBR28 for use in longitudinal studies and clinical trials in Alzheimer’s disease (AD), there is a need to develop non-invasive metrics of tracer binding that do not require arterial cannulation. Recent work has suggested that standardised uptake value (SUV)-based methods may be sensitive to changes in translocator protein (TSPO) levels associated with neurodegeneration. However, the test-retest reliability of these approaches in AD over a time period relevant for clinical trials is unknown. In this study, the test-retest reliability of three SUV-based metrics was assessed in AD patients over 12 weeks. METHODS: Five patients with mild AD and the high-affinity binding TSPO genotype underwent two [(11)C]-PBR28 PET scans approximately 12 weeks apart. The test-retest reliability (TRR) of the unadjusted SUV, SUV relative to cerebellar grey matter (SUVR(C)) and SUV normalised to whole brain activity (SUVR(WB)) in nine cortical and limbic regions of interest was assessed using the absolute variability and the intraclass correlation coefficient. RESULTS: Of the three measures, SUVR(WB) performed best overall, showing low absolute variability (mean −0.13 %, SD 2.47 %) and high reliability (mean ICC = 0.83). Unadjusted SUV also performed well, with high reliability (ICC = 0.94) but also high variability (mean −1.24 %, SD 7.28 %). By comparison, the SUVR(C) showed higher variability (mean −3.98 %, SD 7.07 %) and low reliability (ICC = 0.65). CONCLUSIONS: In this AD sample, we found that SUV-derived metrics of [(11)C]-PBR28 binding showed high stability over 12 weeks. These results compare favourably with studies reporting TRR of absolute quantification of [(11)C]-PBR28. Pending further validation of SUV-based measures of [(11)C]-PBR28, semi-quantitative methods of [(11)C]-PBR28 analysis may prove useful in longitudinal studies of AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-016-0226-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5039146
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-50391462016-10-11 Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer’s disease Nair, Akshay Veronese, Mattia Xu, Xiaohui Curtis, Charles Turkheimer, Federico Howard, Robert Reeves, Suzanne EJNMMI Res Short Communication PURPOSE: In order to maximise the utility of [(11)C]-PBR28 for use in longitudinal studies and clinical trials in Alzheimer’s disease (AD), there is a need to develop non-invasive metrics of tracer binding that do not require arterial cannulation. Recent work has suggested that standardised uptake value (SUV)-based methods may be sensitive to changes in translocator protein (TSPO) levels associated with neurodegeneration. However, the test-retest reliability of these approaches in AD over a time period relevant for clinical trials is unknown. In this study, the test-retest reliability of three SUV-based metrics was assessed in AD patients over 12 weeks. METHODS: Five patients with mild AD and the high-affinity binding TSPO genotype underwent two [(11)C]-PBR28 PET scans approximately 12 weeks apart. The test-retest reliability (TRR) of the unadjusted SUV, SUV relative to cerebellar grey matter (SUVR(C)) and SUV normalised to whole brain activity (SUVR(WB)) in nine cortical and limbic regions of interest was assessed using the absolute variability and the intraclass correlation coefficient. RESULTS: Of the three measures, SUVR(WB) performed best overall, showing low absolute variability (mean −0.13 %, SD 2.47 %) and high reliability (mean ICC = 0.83). Unadjusted SUV also performed well, with high reliability (ICC = 0.94) but also high variability (mean −1.24 %, SD 7.28 %). By comparison, the SUVR(C) showed higher variability (mean −3.98 %, SD 7.07 %) and low reliability (ICC = 0.65). CONCLUSIONS: In this AD sample, we found that SUV-derived metrics of [(11)C]-PBR28 binding showed high stability over 12 weeks. These results compare favourably with studies reporting TRR of absolute quantification of [(11)C]-PBR28. Pending further validation of SUV-based measures of [(11)C]-PBR28, semi-quantitative methods of [(11)C]-PBR28 analysis may prove useful in longitudinal studies of AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-016-0226-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-09-27 /pmc/articles/PMC5039146/ /pubmed/27678494 http://dx.doi.org/10.1186/s13550-016-0226-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Communication
Nair, Akshay
Veronese, Mattia
Xu, Xiaohui
Curtis, Charles
Turkheimer, Federico
Howard, Robert
Reeves, Suzanne
Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer’s disease
title Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer’s disease
title_full Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer’s disease
title_fullStr Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer’s disease
title_full_unstemmed Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer’s disease
title_short Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer’s disease
title_sort test-retest analysis of a non-invasive method of quantifying [(11)c]-pbr28 binding in alzheimer’s disease
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039146/
https://www.ncbi.nlm.nih.gov/pubmed/27678494
http://dx.doi.org/10.1186/s13550-016-0226-3
work_keys_str_mv AT nairakshay testretestanalysisofanoninvasivemethodofquantifying11cpbr28bindinginalzheimersdisease
AT veronesemattia testretestanalysisofanoninvasivemethodofquantifying11cpbr28bindinginalzheimersdisease
AT xuxiaohui testretestanalysisofanoninvasivemethodofquantifying11cpbr28bindinginalzheimersdisease
AT curtischarles testretestanalysisofanoninvasivemethodofquantifying11cpbr28bindinginalzheimersdisease
AT turkheimerfederico testretestanalysisofanoninvasivemethodofquantifying11cpbr28bindinginalzheimersdisease
AT howardrobert testretestanalysisofanoninvasivemethodofquantifying11cpbr28bindinginalzheimersdisease
AT reevessuzanne testretestanalysisofanoninvasivemethodofquantifying11cpbr28bindinginalzheimersdisease